Therapy of Infectious Diseases Among Children and Adults: The Role of Antibiotics in Daily Practice

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1352

Special Issue Editors


E-Mail Website
Guest Editor
Department of Infectious Diseases, Military Medical Academy, Sofia, Bulgaria
Interests: аntibiotic use among children and adults; vector-borne and zoonotic diseases; zoonoses and public health; fever of unknown origin (FUO); medical parasitology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Epidemiology and Hygiene, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria
Interests: childhood infectious diseases; antibiotic therapy; parasitology; foodborne diseases; diseases with diarrheal syndrome

Special Issue Information

Dear Colleagues,

We are excited to announce a call for manuscripts for a Special Issue entitled “Therapy of Infectious Diseases Among Children and Adults: The Role of Antibiotics in Daily Practice”. Authors are invited to submit reviews, original articles, short communications, and case reports in several key aspects:

  • Аntibiotic use among children: practices, trends, problems, and perspectives.
  • Аntibiotic use among adults: practices, trends, problems, and perspectives.
  • Аntibiotic use among outpatients: general characteristics, problems, and recommendations.
  • Аntibiotic use among inpatients: general characteristics, problems, and recommendations.
  • Antibiotic resistance: mechanisms of antibiotic resistance, strategies for its management, and developing new antibiotics.
  • Improper antibiotic use: impact of antibiotic misuse; adverse effects resulting from incorrect dosages; inappropriate prescribing practices.
  • Antibiotic quality control: innovative approaches in the quality control of antibiotics (testing methods, regulatory frameworks, and quality assurance protocols).

We look forward to receiving your manuscripts and the valuable comments they will undoubtedly inspire.

Dr. Magdalena Baymakova
Dr. Valeri R. Velev
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • аntibiotic use among children
  • аntibiotic use among adults
  • аntibiotic use among outpatients
  • аntibiotic use among inpatients
  • antibiotic resistance
  • improper antibiotic use
  • antibiotic quality control

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

11 pages, 239 KiB  
Brief Report
Resistance Patterns of Neisseria gonorrhoeae in PLHIV: A Cross-Sectional Study from the Republic of Cyprus, 2015–2023
by Michaela Takos, George Siakallis, Annalisa Quattrocchi, Maria Alexandrou, Panagiota Papadamou, Loukia Panagiotou and Danny Alon-Ellenbogen
Antibiotics 2025, 14(6), 589; https://doi.org/10.3390/antibiotics14060589 - 7 Jun 2025
Viewed by 475
Abstract
Background: The rise in antimicrobial-resistant (AMR) strains of Neisseria gonorrhoeae is internationally recognised as a critical public health concern, with limited treatment options available. The urgency of this issue prompted the European Centre for Disease Prevention and Control to establish ‘EURO-GASP’ to monitor [...] Read more.
Background: The rise in antimicrobial-resistant (AMR) strains of Neisseria gonorrhoeae is internationally recognised as a critical public health concern, with limited treatment options available. The urgency of this issue prompted the European Centre for Disease Prevention and Control to establish ‘EURO-GASP’ to monitor trends in resistance and address developments. Comprehensive data on AMR strains in people living with HIV (PLHIV) is limited, especially in Cyprus. Objectives: To analyse trends in rates of resistant N. gonorrhoeae infections and identify any correlations between patient factors that may contribute to such in PLHIV in The Republic of Cyprus. Methods: We conducted a retrospective chart review study on N. gonorrhoea resistance among PLHIV from the Gregorios HIV reference clinic in Larnaca, Cyprus, between 2015 and 2023. Antimicrobial susceptibility was assessed via disc diffusion or gradient strip method on GC II agar against a non-homogenous panel of antibiotic preparations, based on standard laboratory practice variation. Demographic and clinical data, including antibiograms, treatments and test of cure, were recorded. Statistical analysis was performed using Stata v16, with significance set at p < 0.05. The study received approval from the Cyprus National Bioethics Committee. Results: A total of 45 isolates from 39 patients were analysed, with 62% of these demonstrating resistance to at least one antibiotic. Resistance rates were not shown to change over time. We identified a statistically significant linear association between a person having a history of an STI and the number of antibiotics which the isolate is resistant to (β = 1.2; p: 0.004). Notably, a single isolate demonstrated resistance to ceftriaxone, the first-line treatment currently recommended in both Europe and the United States. This finding is particularly alarming given the critical role of ceftriaxone in the management of gonorrhoea. Conclusions: Whilst there has been no increase in resistance rates over time, the detection of ceftriaxone-resistant N. gonorrhoeae is a significant public health concern. Given that having a history of an STI makes a person more likely to develop a resistant infection, PLHIV or those who engage in risky sexual behaviours are particularly vulnerable. There is a pressing need to enhance surveillance and implement routine susceptibility testing in Cyprus, given the country’s role as a major international hub for travel and migration. Molecular analysis can further improve our understanding. Additionally, the global public health community must urgently prioritise the development of novel therapeutic agents for the treatment of gonorrhoea. Full article
Back to TopTop